glp 1 digestive support Gut Response GLP-1 Youtheory 2x Action Probiotic GLP-1

Non-pharmacological interventions (weight loss 7-10%, Mediterranean diet, and physical activity) are represented as the therapeutic basis, together with pharmacological strategies under investigation or clinical use (THR- agonists, FGF-21 analogs, pan-PPAR modulators, GLP-1 RAs, GLP-1/GIP, SGLT-2 inhibitors, metformin, and statins)

In fact, in a recently published study in patients with T2D receiving basal/bolus insulin, the addition of a once-weekly GLP-1 RA resulted in more than half of participants no longer requiring mealtime insulin after starting GLP-1 RA therapy

It also has effects on the insulin signaling pathway, contributing to insulin resistance, and involvement in inflammatory processes like obesity and type 2 diabetes mellitus

In conclusion, GLP-1 RAs provide an important therapeutic option for patients with T2D to improve glucose control, mitigate cardiovascular and kidney risk, and facilitate weight loss

Holly Wyatt, an adjoint associate professor in medicine at the University of Colorado Anschutz

The efficacy and safety of -nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: A randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial